

Becoming the apex predator

Improving immunotherapeutic strategies in patients with thoracic malignancies

1. For an effective anti-cancer immune response in SCLC and mesothelioma, it is key to turn their immune profiles into an inflamed phenotype. *(this thesis)*
2. Clinicians ought to be aware of differences between study and real-world population, and preferably, studies should be developed based on the population of patients seen in daily clinical practice. *(this thesis)*
3. The potential synergic role of chemotherapy in addition to immunotherapy is underestimated. *(this thesis)*
4. Data from the Dutch cancer registry show that increasing number of patients with SCLC receive only best supportive care, this doesn't mean we are doing right. *(this thesis)*
5. It is of utmost importance to identify the correct causative agent when noticing toxicity during chemo-immunotherapy treatment. *(this thesis)*
6. Switching ICI treatment from canonical interval dosing to extended interval dosing of immune checkpoint inhibitors does not increase the incidence of immune-related adverse events. *(adapted from Cantini et al. Journal of the National Cancer Institute 2023)*
7. Shared decision in considering anti-cancer treatment is only possible when full diagnostic procedures are completed.

8. The critical benchmark for success with immunotherapy is long-term survival, for which we should focus on the tail of the Kaplan-Meier curve. (*adapted from Chan et al. Oncoimmunology 2019*)
9. Nothing truly valuable can be achieved except by the unselfish cooperation of many individuals. (*Albert Einstein*)
10. Het aanscherpen van de PASKWIL-criteria (Palliatief, Adjuvant, Specifieke bijwerkingen, KWaliteit van leven, Impact van de behandeling en Level of evidence) leidt ertoe dat Nederlandse patiënten minder toegang krijgen tot nieuwe behandelopties en de kans op innovatieve behandelopties wordt ontnomen.
11. Het dienend leiderschap van de alfawolf is een voorbeeld voor de mens om gezamenlijk verder te komen.